AZ’ Calquence granted US Breakthrough Therapy Designation
admin 14th August 2019 Uncategorised 0The drug has been approved for chronic lymphocytic leukaemia. More: AZ’ Calquence granted US Breakthrough Therapy Designation Source: News
read more
The drug has been approved for chronic lymphocytic leukaemia. More: AZ’ Calquence granted US Breakthrough Therapy Designation Source: News
read moreThe approval follows the Positive Opinion from the European Medicines Agency’s CHMP, and marks the fifth European approval in as many years. More: Imbruvica bags EU expansion for two indications Source: News
read moreThe offer hopes to resolve competition concerns over the supply of a fludrocortisone acetate 0.1 mg tablets. More: Aspen to pay NHS £8m after CMS probe Source: News
read morehe companies announced earlier this month that the drug was also successful in prostate cancer. More: Lynparza hits target in late stage ovarian cancer trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals